

is therefore excepting certain categories of persons, as described herein.

This Order will be in effect for 30 days to avert the serious danger of the introduction, transmission, and spread of Ebola disease into the United States. Finally, as directed by 42 CFR 71.40(c), this Order sets out the following:

(1) The foreign countries (or one or more political subdivisions or regions thereof) or places from which the introduction of persons is being prohibited;

(2) The period of time or circumstances under which the introduction of any persons or class of persons into the United States is being prohibited;

(3) The conditions under which that prohibition on introduction will be effective, in whole or in part, including any relevant exceptions that the Director determines are appropriate;

(4) The means by which the prohibition will be implemented; and

(5) The serious danger posed by the introduction of the quarantinable communicable disease in the foreign country or countries (or one or more political subdivisions or regions thereof) or places from which the introduction of persons is being prohibited.

V. Determination and Implementation

Based on the foregoing, I hereby determine that Ebola disease, a highly transmissible quarantinable communicable disease, is confirmed currently present in DRC and recently present in Uganda. There is a material risk that the outbreak will spread to South Sudan. I also determine that the prevalence of Ebola disease in these foreign countries constitutes a serious danger of the introduction of this disease into the United States due to the limited screening and testing and mitigation measures currently available. Finally, I determine that a temporary 30-day suspension of the right to introduce covered aliens is necessary to protect the public health from the serious danger of the introduction of Ebola disease into the United States, pending an ongoing public health assessment of the Ebola disease outbreak.

I consulted with the Department of State, DHS, and other federal departments as needed before I issued this Order and requested that DHS aid in the enforcement of this Order because CDC does not have the capability, resources, or personnel needed to do so.²⁸ As part of the consultation, DHS developed operational plans for implementing this Order. These plans are consistent with the language of this Order.

Although this Order is not a rule subject to notice and comment under the Administrative Procedure Act (APA) and is issued with immediate effect, in order to ensure that the forthcoming public health risk assessment is informed by public input, the Order is being issued with a simultaneous 15-day comment period.

This Order takes effect at 5:00 p.m. Eastern Daylight Time on Wednesday, August 12, 2026. For individuals intending to travel to the United States by air, the Order will apply

to flights departing after 4:59 p.m. Eastern Daylight Time on Wednesday, August 12, 2026.

* * * * *

In testimony whereof, the Assistant Secretary for Health, U.S. Department of Health and Human Services, has hereunto set his hand at Washington, DC this 12th day of August, 2026.

Dated: Admiral Brian Christine, MD, Assistant Secretary for Health (ASH) and Head of the United States Public Health Service (USPHS) Commissioned Corps Department of Health and Human Services.

Public Participation

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data so that the public can provide input that may inform the forthcoming public health risk assessment and whether any subsequent exercise of this authority is necessary.

Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on <https://www.regulations.gov>. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. Do not submit comments by email. CDC does not accept comment by email.

Authority

The authority for this order is Sections 362 and 365 of the Public Health Service Act (42 U.S.C. 265 and 268), as amended.

Brian Christine,

Assistant Secretary for Health (ASH) and Head of the United States Public Health Service (USPHS) Commissioned Corps, Department of Health and Human Services.
[FR Doc. 2026-16706 Filed 8-14-26; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Sole Source Cooperative Agreement To Fund the Ministry of Health of Ethiopia

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$30,000,000, for Federal Fiscal Year 2026 funding to the Ministry of Health (MOH), subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. The award is expected to help build and oversee national HIV and TB programs in Ethiopia through the MOH and its affiliates.

DATES: The period for this award will be September 30, 2026, through September 29, 2031.

FOR FURTHER INFORMATION CONTACT: Cristel Bender, Global Health Center, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, Email: DGHTNOFOs@cdc.gov.

SUPPLEMENTARY INFORMATION: The sole source award is intended to help build and oversee national HIV and TB programs in Ethiopia through the MOH and its affiliates.

The Ethiopia MOH is the only entity that can carry out this work, as it is the primary authority responsible for overseeing the health care system in Ethiopia, including preventing, providing care, and treating HIV/AIDS, mandated under Proclamation No. 1263/2021.

Summary of the Award

Recipient: Ministry of Health (MOH).

Purpose of the award: The purpose of this award is to lead and coordinate the national HIV and TB program, helping to ensure sustainable, cost effective, high-quality life-saving HIV services at national and regional levels.

Authority: This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) [22 U.S.C. 7601, *et seq.*] and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008),

²⁸ 42 U.S.C. 268; 42 CFR 71.40(d).

and Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013).

Additionally, these programs are authorized under Section 307 of the Public Health Service Act, as amended [42 U.S.C. 242l], Section 301 (a) [42 U.S.C. 241 (a)] of the Public Health Service Act, as amended.

Period of performance: September 30, 2026, through September 29, 2031.

Jamie Legier,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2026–16731 Filed 8–14–26; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Sole Source Cooperative Agreement To Fund University Teaching Hospital in Zambia

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$30,000,000, for Federal Fiscal Year 2026 funding to Zambia's University Teaching Hospital (UTH), subject to availability of funds. Funding amounts for years 2–5 will be set at continuation. The award is expected to improve HIV and TB clinical and laboratory service delivery at referral level hospitals and provincial-level referral facilities through the national government referral facility, UTH.

DATES: The period for this award will be September 30, 2026, through September 29, 2031.

FOR FURTHER INFORMATION CONTACT: Cristel Bender, Global Health Center, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA 30329, Email: DGHTNOFOs@cdc.gov.

SUPPLEMENTARY INFORMATION: The sole source award is expected to improve HIV and TB clinical and laboratory service delivery at referral level hospitals and provincial-level referral facilities through the national government referral facility, UTH.

UTH is the only entity that can carry out this work, as it is the country's national reference hospital, with a directive to provide inpatient and

outpatient services for complicated cases, including advanced HIV disease cases.

Summary of the Award

Recipient: University Teaching Hospital.

Purpose of the award: The purpose of this award is to support sustainable HIV and TB service implementation through UTH.

Authority: This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) [22 U.S.C. 7601, *et seq.*] and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013), and Public Health Service Act (42 U.S.C. 242l).

Period of performance: September 30, 2026, through September 29, 2031.

Jamie Legier,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2026–16732 Filed 8–14–26; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Withdrawal of the Announcement of the Intent To Award a Single-Source Cooperative Agreement to Burke Law Group, PLLC in Houston, Texas

AGENCY: Office of Refugee Resettlement (ORR), Administration for Children and Families (ACF), Department of Health and Human Services (HHS).

ACTION: Notice of intent to award a single-source cooperative agreement; withdrawal.

SUMMARY: The Administration for Children and Families (ACF), Office of Refugee Resettlement (ORR), is withdrawing the, 'Announcement of the Intent to Award a Single-Source Cooperative Agreement to Burke Law Group, PLLC in Houston, Texas' published in the **Federal Register** on August 6, 2026, at 91 FR 50848 (FR Doc. 2026–16081).

FOR FURTHER INFORMATION CONTACT: Reina Byrd, Assistant Deputy Director, Unaccompanied Alien Children Bureau, 330 C St SW, Washington, DC 20201. Telephone: (202) 256–9497; Email: Reina.Byrd@acf.hhs.gov.

SUPPLEMENTARY INFORMATION:

Withdrawal Notice

In the **Federal Register** of August 6, 2026, at 91 FR 50848 (FR Doc. 2026–16081), page 50848, ORR published a notice announcing its intent to award a single-source cooperative agreement of up to \$150,000,000 to Burke Law Group, PLLC, in Houston, Texas, to provide legal services for eligible unaccompanied alien children (UAC) in ORR care.

Burke Law Group subsequently notified ORR of its decision not to apply for the proposed cooperative agreement and withdrew from consideration on August 11, 2026. Therefore, ORR will not make the award to Burke Law Group announced in the notice published on August 6, 2026. This withdrawal does not affect ORR's continued efforts to ensure access to legal services for eligible UACs in ORR care.

Statutory Authority: Section 462 of the Homeland Security Act of 2002, 6 U.S.C. 279; William Wilberforce Trafficking Victims Protection Reauthorization Act of 2008, 8 U.S.C. 1232(c)(4) and (c)(5).

Dawnisha Helland,

Assistant Principal Deputy Director, Unaccompanied Alien Children Bureau, Office of Refugee Resettlement.

[FR Doc. 2026–16741 Filed 8–13–26; 11:15 am]

BILLING CODE 4184–45–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–D–5376]

Type VII Veterinary Master File for Research and Development and Risk Reviews; Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry (GFI) #260 entitled "Type VII Veterinary Master File for Research and Development and Risk Reviews." This guidance describes FDA's current thinking regarding the use of Type VII Veterinary Master Files (Type VII VMFs). Type VII VMFs are appropriate for research and development of animal cells, tissues, and cell- and tissue-based products (ACTPs), gene therapies, and heritable intentional genomic alterations (IGAs) in animals.